Oxidized lipids in atherogenesis: Formation, destruction and action

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 195-199

  Berliner, Judith ^a,b   Leitinger, Norbert ^a   Watson, Andrew ^a   Huber, Joakim ^a   Fogelman, Alan ^a   Navab, Mohamad ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID;

ATHEROGENESIS; CONFERENCE PAPER; LIPID METABOLISM; PRIORITY JOURNAL;

EID: 0030877832     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657525     Document Type: Conference Paper

References (34)

1. Parthasarathy S and Rankin SM. The role of oxidized LDL in atherogenesis. Prog Lipid Res. 31: 127-143,1992
2. Witzum JL Steinberg D Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1785-1792,1991
3. Endemann,G; Stanton, LW; Madden, KS; Bryant, CM; White, R T; Protter, A A CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268:11811-11816; 1993.
4. Ramprasad MP, Fischer W, Witztum JL, Sambrano GR, Quehenberger O and Steinberg D. The 94 to 97 KD mouse macrophage membrane protein that recognizes oxidized LDL and phosphatidylserine rich liposomes is identical to macrosialin, the mouse homologue of CD68. Proc Natl Acad Sci US 92:9580-9584, 1995.
5. Hughes H, Matthews B, Lenz ML and Guyton JR. Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7 ketochol7esterol and 7-hydroxycholesterol. Arterioscler. Thromb. 14:1177-1184, 1994.
6. Colles SM, Irwin KC and Chisolm GM. Role of multiple oxidized LDL lipids in cellular injury: dominance of 7 beta-hydroperoxycholesterol. J Lipid Res 37:2018-2028, 1996.
7. Reid, V C; Mitchinson, M J. Toxicity of oxidized LDL towards mouse peritoneal macrophages in vitro. Atherosclerosis 98: 17-24, 1993.
8. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD and Lusis AJ. Atherosclerosis: Basic Mechanisms: Oxidation, Inflammation and Genetics. Circulation 91: 2488-2496,1995.
9. Berliner JA and Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radicals in Biol and Med.20:707-727,1996.
10. Weis, J R; Pitas, R E; Wilson, B D; Rodgers. Oxidized LDL increases cultured human endothelial cell tissue factor activity and reduces protein C activation. G M Faseb J. 5:2459-65,1991.
11. Drake TA, Hannani K, Fei H, Lavi S and Berliner JA. MM-LDL induces tissue factor expression in cultured human endothelial cells. Am J Pathol 138:601-607
12. Brand, L; Banka, CL; Madmann, Terkillaub, PA; Faust, Curtiss, L. K. Oxidized LDL entrance LPS induced tissue factor expression in adherent monocytes, Arterioscler. Thromb. 14: 790-797, 1994.
13. Tipping PG, Davenport P, Gallicchio M, Filonzi EL, Apostolopoulos J and Wojta J. Atheromatous plaque macrophages produce PAI-1 and stimulate its production by endothelial cells and smooth muscle cells. Am J Path 143: 875-885, 1993.
14. Murugesan, G; Chisolm, G M; Fox, P L Oxidized low density lipoprotein inhibits the migration of aortic endothelial cells in vitro. J. Cell Biol. 120:1011-1019; 1993.
15. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, La Du BN, Fogelman AM and Berliner, JA. Effect of Platelet Activating Factor-Acetylhydrolase on the Formation and action of minimally oxidized LDL. J Clin Invest.95: 774-782, 1995
16. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM and Navab M. Protective effect of HDL associated paraoxonase - inhibition of the biological activity of minimally oxidized LDL. J Clin Invest.95: 2882-2891,1995.
17. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder G, Fogelman AM and Berliner JA. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized LDL that induce monocyte/endothelial interactions and evidence fro their presence in vivo. J Biol Chem. In Press
18. Liao F, Andalibi A, deBeer F, Fogelman AM and Lusis AJ. Genetic control of inflammatory gene induction and nf-kB like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest 91: 2572-2579, 1993.
19. Liao F, Andalbi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction and aortic fatty streak formation in mice. J Clin Invest. 94: 877-884, 1994.
20. Ohara Y, Petersen TE and Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546-2551, 1993.
21. VanLenten, B.J., Prieve J., Navab, M., Hama, S., Lusis, A.J., Fogelman, A.M.: Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J. Clin Invest 95:2104-2110, 1995.
22. Lynch SM and B Frei. Antioxidants as Anti-Atherogens: Animal Studies. In "Natural Antioxidants in Human Health & Disease". Ed. B. Frei. Academic Press, Orlando, FL, 1994
23. Palinski W, Miller E and Witztum JL. Immunization of LDL receptor deficient rabbits with homologous MDA-LDL reduces atherogenesis.Proc. Natl. Acad Sci. 92:821-825, 1995.
24. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA and Fogelman AM. The Yin and Yang of oxidation in the development of the fatty streak. Arteroscler. Thromb. Vasc. Biol. 16:831-842, 1996.
25. Stafforini DM, immerman GA, McIntyre TM, Prescott SM. The platelt activating factor acetylhydrolase from human plasma prevents oxidative modification of LDL. Trans Assoc Am Physicians 105:44-63, 1993.
26. Mackness MI, Arrol D, durrington P. Paraoxonase prevents accumulation of lipoperoxides in LDL. FEBS Lett. 286: 152-154, 1991.
27. Dentan C, Lesnik M, Chapman J, Ninjo E. PAF acether degrading acetylhydrolase in plasma is inactivated by copper and cell mediated oxidation. Arterioscer. Thromb. 14:353-360,1994.
28. Ameli SA, Hltgardh-Nillson A, Regnstrom J, Caldara F, Yano J, Cercek B, Shah PK and Nilsson J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16: 1074-1079, 1996.
29. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC and Berliner JA. Minimally modified LDL induced inflammatory responses in endothelial cells are mediated by cyclic adensosine monophosphate. J Clin Invest 92:471-478,1993.
30. Khan BV, Parthasarathy S, Alexander RW and Medford RM. Modified LDL and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 95:1262-1270, 1995.
31. Rajavashisth TB, Yamada H and Mishra NK. Transcriptional activation of the MCSF gene by minimally modified LDL: Involvement of NFkB. Arterioscler. Thromb. Vasc. Biol. 15: 1591-1598, 1995.
32. Uyemura K, Demer LL, Castle SC, Julien D, Berliner JA, Gately MK, Warrier RR, Phain N, Fogelman AM and Modlin RI. Cross Regulatory Roles of IL-12 and IL-10 in atherosclerosis. J Clin Invest 97: 2130-2138, 1996.
33. Johansson J, Olsson AG, Bergstrand L, Elinder LS, Nilsson S, Erikson U, Molgaard J, Holme I and Walldius G. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A PQRST Report. Arterioscler. Thromb. Vasc. Biol. 15:1049-56, 1995.
34. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K and Mitchinson MJ. Randomized controlled trial of vitamin E in patients with coronary disease. CHAOS study. Lancet 347: 781-786, 1996.